Efficacy and Dose Ranging Study of Seroguard

NCT03660787 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Adhesion

Interventions

DRUG: Seroguard
DRUG: Placebo

Sponsor

Pharmasyntez

Collaborators

[object Object]